When I use a word . . . Commercial clinical trials

A reviewEarlier this year, the UK government appointed Lord James O’Shaughnessy, senior partner at a consultancy firm, Newmarket Strategy, a board member of Health Data Research UK, and a former Conservative health minister, to conduct an independent review into what was described as “the UK commercial clinical trials landscape.”1The background to this review was that there had reportedly been a 44% fall in recruitment of patients to phase 3 commercial clinical trials between 2017 and 2021. This had had the effect, according to an analysis by the Association of the British Pharmaceutical Industry (ABPI), of dropping the UK down the global rankings for numbers of phase 3 industry sponsored clinical trials from fourth place in 2017, after the USA, Germany, and Spain, to 10th in 2021, now behind the USA, China, Spain, Japan, Germany, Canada, France, Poland, and Italy.2 This was despite the fact that during the same time the…
Read Original Article: When I use a word . . . Commercial clinical trials »